GemBCG (intravesical gemcitabine + BCG immunostimulation) delivers 96% 6‑mo CR in BCG-exposed high‑grade NMIBC

GemBCG combines intravesical gemcitabine (a DNA synthesis–inhibiting antimetabolite chemotherapy) with intravesical BCG (live-attenuated mycobacterial immunotherapy) in an alternating schedule to intensify local chemoimmunologic pressure in the bladder. In the initial Phase 1 dose-escalation cohort of patients with BCG-exposed high-grade NMIBC (n=25; 68% CIS±papillary; NCT04179162), no treatment-related grade ≥3 AEs or DLTs were seen (72% grade 1; 20% grade 2), and 24/25 patients achieved a 6-month complete clinical response (96%, 95% CI 80%–100%). An expanded Phase 1/2 dataset (n=52) subsequently reported grade 3 treatment-related AEs in 2 patients (3.8%), with no grade 4–5 treatment-related events, supporting a generally favorable but not toxicity-free safety profile. The 6-month CR rate is notably higher than what’s typically expected with BCG re-induction alone in BCG-exposed/persistent populations (~50% CR at 6 months in guideline-era summaries, and ~90% CR at 3 months with a second induction in some retrospective series, with durability being the usual limitation), setting a high bar for the ongoing randomized Phase 3 Alliance A032303 comparing GemBCG vs BCG alone (NCT07000084).